pharmaphorum

JANUARY 29, 2023

While global health spending per capita was about US$1,100 in 2018, this is forecast to rise to US$1,700 by 2026, outpacing GDP growth over the same period. For instance, these technologies act as key enablers in telehealth, e-prescriptions, the use of robots for simple operations, and smart hospitals.

Healthcare 98

Healthcare Healthcare Manufacturing Marketing 98

PM360

APRIL 7, 2023

This is especially significant for manufacturers of high-cost specialty drugs, who will now face a recurring additional 20% charge on virtually every prescription fill. On the other side, drug manufacturers are facing the squeeze, with caps on price inflation and a mandated 20% discount in the catastrophic phase.

Manufacturing 97

Manufacturing Insurance Government Marketing 97

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. Figure 1: Share of net spending for specialty and traditional prescription medications. The Uses—and Costs—of Specialty Treatments Keep Rising A U.S.

Prescription 52

Prescription Medical Patients Distribution 52

Pharmaceutical Technology

JANUARY 31, 2023

Inflation Reduction Act Speaking during the keynote panel “FDA & ARPA-H: Life Sciences, Biopharma & Medtech Priorities in a New Year”, Califf discussed the Inflation Reduction Act of August 2022, which aims to lower prescription drug prices.

FDA 52

FDA Prescription Medicine Biopharma 52

pharmaphorum

JUNE 29, 2022

The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026.

Doctors 59

Doctors Medicine Marketing Sales 59

PM360

SEPTEMBER 28, 2022

In April 2022, we released an article describing proposed policies from the federal government that could impact prescription drug pricing. The facts: All Part D beneficiaries will pay $0 out of pocket for prescriptions in the catastrophic phase. On August 16, 2022, President Biden signed the Inflation Reduction Act (IRA) into law.

Government 97

Government Manufacturing Prescription Competition 97

Pharmaceutical Technology

AUGUST 12, 2022

The Act authorizes the appropriation of $100,000,000 per fiscal year from 2022 to 2026. Timely reauthorization of the Prescription Drug User Fee Act by Congress will help ensure FDA can keep pace with the number and complexity of new medicines entering the review pipeline.”. The future of ALS research.

FDA 98

FDA Food and Drug Administration Physicians Side effects 98

Clarivate

AUGUST 20, 2024

Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Pharmaceutical Technology

JANUARY 16, 2023

The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023.

Pharma 64

Pharma Pharmaceutical Manufacturing Marketing 64

Pharmaceutical Technology

JANUARY 16, 2023

The legislation contains several provisions to lower prescription drug costs, including allowing Medicare to negotiate the cost of selected medicines. Negotiated prices will not apply until 2026, but the selected medicines for Medicare price negotiations will be unveiled in September 2023.

Pharma 52

Pharma Pharmaceutical Manufacturing Marketing 52

World of DTC Marketing

JULY 28, 2022

Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. Nearly 9 in 10 older adults take prescription medication. Still, the pharma industry is fighting hard to keep it off the table.

Pharma 256

Pharma Prescription Pharmaceutical Manufacturing 256

Clarivate

OCTOBER 17, 2024

Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries. Such a change would sharply increase the number of people covered under this program.

Healthcare 52

Healthcare Healthcare Government Insurance 52